ClinicalTrials.gg
Not yet recruitingNCT07932613Updated Nov 12, 2026

Effect of Metaxalone 640 mg (M640) on Driving, Cognition, and EEG Dynamics Compared to Tizanidine 8 mg in Adults

A Phase 4 interventional study of Metaxalone Pill and tizanidine 8 mg in Healthy Participant, sponsored by Primus Pharmaceuticals. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Primus Pharmaceuticals · Phase 4, Interventional, and Basic science

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Participant takes a single pill after eating, takes a driving test on a simulator, takes thought and concentration computerized tests

Read the detailed description

The study evaluates effects of a single-dose of M640 mg compared to a single dose of tizanidine 8 mg on driving, cognition, sleepiness, and brain activity in healthy adults

02

Conditions studied

  • Healthy Participant

Keywords

  • driving, cognition, EEG, muscle relaxer
03

In context

Lead sponsor

Primus Pharmaceuticals is the lead sponsor of 21 studies on the registry; 4 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults, aged ≥ 18 and ≤ 65 years of age at the time of consent.
  • Weigh at least 120 pounds at Screening/Baseline and Baseline.
  • Medically healthy
  • Able to take oral medication.
  • Possesses a valid driver's license.

Exclusion criteria

Exclusion Criteria:

  • Current use of any medications known to affect sleep-wake cycle.
  • Has a sleep disorder.
  • Positive urine test for amphetamines, barbiturates, cocaine, opiates, benzodiazepines, or cannabinoids
  • Known history of alcohol or substance use disorder
  • Participants with a history of cognitive disorders, depression, schizophrenia, panic disorder, or dementia.
  • Participants with a history of seizure disorder or epilepsy.
  • Participants with scalp conditions, dermatologic disease, or hair/scalp characteristics
05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Active metaxalone 640 mg

    metaxalone 640 mg tablets, one dose only

    Drug: Metaxalone Pill

  • Active comparator
    Active tizanidine 8 mg

    tizanidine 8 mg tablets, one dose only

    Drug: tizanidine 8 mg

Interventions

  • micronized metaxalone 640 mg pill

    Also known as: m640, Skelaxin 640 mg

  • muscle relaxer for spasms

    Also known as: Zanaflex

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Tmax in Standard Deviation of Lateral Position as evaluated by Driving Simulation Software

    A hardware and software setup that recreates the experience of driving a real vehicle and measures performance at the time of maximum concentration of the drug in the body (metaxalone 4 hours and tizanidine 1.5 hours post dose)

    Time frame: Baseline dose to time of maximum concentration (Tmax), metaxalone 4 hours and tizanidine 1.5 hours post dose

  2. Change from Baseline to Tmax in Cognition as assessed by Creyos Cognitive Testing (CCT).

    Computerized thinking assessment to objectively measure brain function at the time of maximum concentration of the drug in the body (metaxalone 4 hours and tizanidine 1.5 hours post dose)

    Time frame: Baseline dose to time of maximum concentration (Tmax), metaxalone 4 hours and tizanidine 1.5 hours post dose

Secondary outcomes

  1. Change from Baseline to Tmax in Degree of point-in-time drowsiness as measured by the Karolinska Sleepiness Scale (KSS).

    Measure at Tmax (metaxalone 4 hours and tizanidine 1.5 hours post dose) Scale: 1 = Extremely alert, 2 = Very alert, 3 = Alert, 4 = Rather alert, 5 = Neither alert nor sleepy, 6 = Some signs of sleepiness, 7 = Sleepy, but no effort to keep awake, 8 = Sleepy, some effort to keep awake, 9 = Very sleepy, great effort to keep awake, fighting sleep

    Time frame: Baseline dose to time of maximum concentration (Tmax), metaxalone 4 hours and tizanidine 1.5 hours

  2. Change from Baseline to Tmax in electroencephalograph measures

    Placement of a non-invasive headset with saline filled, padded electrodes on the participant's scalp to measure brain activity with eyes open and closed at the time of maximum dose of the drug in the body (metaxalone 4 hours and tizanidine 1.5 hours post dose)

    Time frame: Baseline dose to time of maximum concentration (Tmax), metaxalone 4 hours and tizanidine 1.5 hours post dose

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 12, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Jul 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07932613
Lead sponsor
Primus Pharmaceuticals
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Jul 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

James Lukban, D.O.
Contact
jlukban@primusrx.com
480-483-1410
Manar Shahbandar
Contact
mshahbandar@primusrx.com
4804831410
James Lukban, DO
study director · Primus Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metaxalone · Tizanidine

Start the discussion